Inception Return
(7/8/2008)
|
10.10 %
|
|
YTD Return
|
-5.48 %
|
|
NAVPS
(12/2/2024)
|
$19.60
|
|
Change
|
($0.04) / -0.22 %
|
|
|
Growth of $10,000
(As of October 31, 2024)
|
|
MER
|
2.44 %
|
|
Assets ($mil)
|
$220.25
|
|
Rank (1Yr)
|
259/265
|
|
Std Dev (3Yr)
|
14.50 %
|
|
Volatility Ranking (3Yr)
|
7/10
|
|
RRSP Eligibility
|
Yes
|
|
Load
|
Choice of Front or No Load
|
|
Max Front End
|
5.00 %
|
|
Max Back End
|
-
|
|
Sales Status
|
Capped
|
|
|
Objective
Long-term capital growth. The Fund seeks to provide above average long-term returns by investing in securities of global, small-cap companies. The Fund is primarily invested in equity securities of companies located around the world. The amount invested in any one country varies depending upon the economic, investment, and market outlook and opportunities in each area. The Fund may also invest in treasury bills or short-term investments, not exceeding three years to maturity, from time to time.
|
Fund Manager
Manulife Investment Management Limited
Portfolio Manager
Manulife Investment Management Limited
Sub-Advisor
Paul Moroz, Mawer Investment Management Ltd.
Christian Deckart, Mawer Investment Management Ltd.
|
|
Asset Allocation
(As of September 30, 2024)
|
Sector Allocation
(As of September 30, 2024)
|
Geographic Allocation
(As of September 30, 2024)
|
Top 10 Holdings
| Name | Asset | Sector | Geographic | Percent |
| Ipsos SA | International Equity | Consumer Services | European Union | 5.50% |
| De' Longhi SpA | International Equity | Consumer Goods | European Union | 4.97% |
| Donnelley Financial Solutions Inc | US Equity | Industrial Services | United States | 4.83% |
| Hikma Pharmaceuticals PLC | International Equity | Healthcare | European Union | 4.82% |
| Alten SA | International Equity | Technology | European Union | 4.48% |
| Gps Participacoes e Empreendimentos SA | International Equity | Industrial Services | Latin America | 4.17% |
| Orkla ASA | International Equity | Consumer Goods | Other European | 3.80% |
| Electrocomponents PLC | International Equity | Technology | European Union | 3.58% |
| Fagron NV | International Equity | Healthcare | European Union | 3.53% |
| Dermapharm Holding SE | International Equity | Healthcare | European Union | 3.49% |
Performance Data
(As of October 31, 2024)
|
|
Return (%)
|
Annualized Return (%)
|
|
Return
|
1
Mth
|
3
Mth
|
6
Mth
|
YTD
|
1
Yr
|
3
Yr
|
5
Yr
|
10
Yr
|
|
Fund
|
-6.18
|
-7.57
|
-4.01
|
-5.48
|
4.78
|
-5.30
|
2.02
|
7.10
|
|
Benchmark
|
0.86
|
2.61
|
10.28
|
14.94
|
30.02
|
5.07
|
9.11
|
9.28
|
|
Quartile Ranking
|
4
|
4
|
4
|
4
|
4
|
4
|
4
|
3
|
|
Calendar Return (%)
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
|
Fund
|
13.25
|
-18.63
|
4.10
|
14.40
|
24.07
|
-3.62
|
20.80
|
-1.30
|
30.70
|
10.97
|
|
Benchmark
|
14.59
|
-13.14
|
15.50
|
11.07
|
20.09
|
-7.34
|
15.40
|
7.47
|
16.61
|
9.59
|
|
Quartile Ranking
|
2
|
3
|
4
|
3
|
1
|
1
|
1
|
4
|
1
|
2
|